Our results also show that METPlatform could be used to validate experimental therapeutic strategies in human samples, where DEBIO‐0932 impairs the viability of the majority of BrM‐PDOC although with different response rates and independently of their primary tumor origin and established HSP90‐dependent oncogenes routinely scored in the clinical practice. The gene discussed is HSP90AA1; the disease is neoplasm.